IS8129A - Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða - Google Patents

Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Info

Publication number
IS8129A
IS8129A IS8129A IS8129A IS8129A IS 8129 A IS8129 A IS 8129A IS 8129 A IS8129 A IS 8129A IS 8129 A IS8129 A IS 8129A IS 8129 A IS8129 A IS 8129A
Authority
IS
Iceland
Prior art keywords
phenyl
methylamide
paroxetine
piperazin
anxiety
Prior art date
Application number
IS8129A
Other languages
English (en)
Inventor
Melotto Sergio
Corsi Mauro
Carletti Renzo
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8129A publication Critical patent/IS8129A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8129A 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða IS8129A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004122 WO2004091616A1 (en) 2003-04-17 2004-04-16 Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety

Publications (1)

Publication Number Publication Date
IS8129A true IS8129A (is) 2005-11-15

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8128A IS8128A (is) 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS8128A IS8128A (is) 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða

Country Status (18)

Country Link
US (4) US20060241124A1 (is)
EP (4) EP1613325A1 (is)
JP (4) JP2006523651A (is)
KR (2) KR20060003876A (is)
CN (2) CN1809355A (is)
AU (2) AU2004229181A1 (is)
BR (2) BRPI0409379A (is)
CA (2) CA2522313A1 (is)
CO (1) CO5700753A2 (is)
GB (1) GB0308968D0 (is)
IS (2) IS8128A (is)
MA (2) MA27730A1 (is)
MX (2) MXPA05011063A (is)
NO (2) NO20055367L (is)
PL (2) PL377858A1 (is)
RU (2) RU2005135647A (is)
WO (4) WO2004091616A1 (is)
ZA (2) ZA200508067B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
HK1045308A1 (zh) * 1999-12-17 2002-11-22 Schering Corporation 选择性神经激肽拮抗物
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
JP4459621B2 (ja) * 2001-11-13 2010-04-28 シェーリング コーポレイション Nk1アンタゴニスト
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2006523651A (ja) 2006-10-19
KR20060003875A (ko) 2006-01-11
US20060217395A1 (en) 2006-09-28
BRPI0409379A (pt) 2006-04-25
PL377857A1 (pl) 2006-02-20
JP2006523650A (ja) 2006-10-19
MXPA05011064A (es) 2006-04-18
PL377858A1 (pl) 2006-02-20
CA2522311A1 (en) 2004-10-28
CN1809359A (zh) 2006-07-26
WO2004091624A1 (en) 2004-10-28
AU2004229181A1 (en) 2004-10-28
RU2005135647A (ru) 2006-06-10
JP2006523652A (ja) 2006-10-19
BRPI0409377A (pt) 2006-04-25
CO5700753A2 (es) 2006-11-30
IS8128A (is) 2005-11-15
JP2006523649A (ja) 2006-10-19
WO2004091617A1 (en) 2004-10-28
ZA200508067B (en) 2007-02-28
NO20055367L (no) 2005-11-14
KR20060003876A (ko) 2006-01-11
CN1809355A (zh) 2006-07-26
US20060241124A1 (en) 2006-10-26
EP1615641A1 (en) 2006-01-18
ZA200508068B (en) 2007-02-28
EP1613325A1 (en) 2006-01-11
AU2004229179A1 (en) 2004-10-28
WO2004091616A1 (en) 2004-10-28
US20060241143A1 (en) 2006-10-26
GB0308968D0 (en) 2003-05-28
US20060287325A1 (en) 2006-12-21
EP1615642A1 (en) 2006-01-18
MA27731A1 (fr) 2006-01-02
EP1653956A1 (en) 2006-05-10
CA2522313A1 (en) 2004-10-28
NO20055368L (no) 2005-11-14
WO2004091615A1 (en) 2004-10-28
RU2005135649A (ru) 2006-03-20
MXPA05011063A (es) 2005-12-12
MA27730A1 (fr) 2006-01-02

Similar Documents

Publication Publication Date Title
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
PE20120252A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
MX2010006238A (es) Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
EA200870019A1 (ru) Лактамовые соединения и способы их применения
UA100364C2 (xx) Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
DK3889142T3 (da) 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MA27192A1 (fr) Derives de n- (phenyl(piperidin-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
ITMI20050262A1 (it) Sostanze composizioni e metodi di trattamento dell'alopecia
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
EE200100335A (et) 4-(aminometüül)piperidiinbensamiidid, vaheühendid, farmatseutiline kompositsioon ja nende valmistamismeetodid
EP1786428A4 (en) PDE5 INHIBITOR COMPOSITIONS AND METHOD FOR TREATING DISEASE
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
IS8129A (is) Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða
NO20085052L (no) 4-((fluorofenoksyl)fenylmetyl)piperidin metansulfonat: anvendelser, synteseprosess og farmasoytiske sammensetninger
ATE471315T1 (de) Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
FR2862968B1 (fr) Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique